Osteoporosis increases bone fragility and fracture risk. Cell-based approaches are being investigated, but a laboratory finding about mesenchymal stromal/stem cells does not establish that an offered preparation prevents fractures or restores normal bone in patients. The first cited paper discusses cell-fate mechanisms and possible applications; it is not proof of a specific osteoporosis protocol. [1]
Bone & Cartilage Diseases
Diseases of the skeletal system are pretty standard for the elderly population and are generally considered to be one of the primary causes of physical disability and morbidity. The most common diseases of the skeletal system include:
- Bone fractures
- Osteoporosis
- Sarcopenia
- Osteoarthritis (OA)
- Rheumatoid arthritis (RA)
- Femoral cartilage degeneration
- Intervertebral disc disease (IVD)
- Lumbar Spinal Stenosis
- Degenerative Disc Disease (DDD)
- Osteogenesis imperfecta (OI)
Fracture prevention, pain, mobility, bone density and bone strength are different outcomes. A proposed cell intervention needs evidence for the actual outcome being discussed, with an appropriate comparison and follow-up. Information about hand and wrist injuries does not establish that a cell protocol prevents osteoporotic fractures.
Stem Cell Treatment for Osteoporosis
The Regeneration Center provides information and individual clinical assessment. A discussion of cell-based intervention should specify the cell preparation, proposed goal, evidence, alternatives and risks. Describing a laboratory mechanism does not establish that treatment is risk-free or reverses bone loss in patients.
Osteoporosis care aims to reduce fracture risk and preserve function. Existing care should be evaluated on its clinical outcomes rather than dismissed as merely stopping bone thinning. The cited 2019 paper reviews prospects for MSC-based approaches; it does not establish efficacy of a particular offered preparation. [3]
Researchers study osteogenic differentiation, signaling, inflammation and interactions within bone marrow. Changes in those mechanisms are different from a demonstrated reduction in fractures or improved function in patients. A claim about a cell intervention should state which evidence supports each step, rather than treating a proposed mechanism as a clinical result.
Importantly, osteoporosis management still requires a comprehensive plan, because cells alone cannot counteract ongoing drivers of bone loss. A proper evaluation typically includes a DEXA scan (T-score), fracture-risk assessment, vitamin D status, calcium balance, thyroid and parathyroid function, sex hormone status when relevant, and screening for secondary causes such as corticosteroid exposure or malabsorption. Protein intake, resistance training, fall-risk reduction, and correction of vitamin D deficiency are foundational and often determine the effectiveness of any advanced therapy. When framed this way, regenerative medicine is best viewed as a potential adjunct strategy, particularly for patients who remain at risk despite conventional options or who cannot tolerate standard medications, rather than a replacement for evidence-based osteoporosis care.
Bone Regeneration Therapy
Cell and extracellular-vesicle studies investigate mechanisms that may be relevant to bone biology. The 2022 reference reviews signaling pathways and research on MSCs and exosomes. It should not be represented as a clinical trial proving that a particular infusion regenerates bone or as evidence that the preparation is immune-privileged or free of relevant risks. [4]
Osteoporosis is a long-term, chronic skeletal condition that is more prevalent among older people. Therefore, reduced bone mass and mineral density are often to blame for most elderly people having fractures. Additionally, osteoporosis is attributed to an imbalance in bone cells. It is characterized by low bone mass and microstructural degradation of bone tissue, which increases bone fragility and fracture risk. Compared to other portions of the bone, the proximal ends of the humerus and femur, the distal end of the radius, and the vertebral column are more prone to osteoporotic fractures. In addition, hip fractures are a significant catalyst for death and high morbidity rates. In recent years, stem cell therapies have attracted considerable attention to the field of tissue engineering and regenerative medicine to treat various disorders and degenerative orthopedic issues such as DDD lower back pain, knee injuries, shoulder injuries, spinal injuries, and osteoarthritis.
Stem Cells’ Role in Osteoporosis & Bone Remodeling
Osteoporosis has multiple contributing factors. Researchers investigate progenitor-cell behavior and signals involved in bone remodeling. An observation about a growth factor or a cell’s behavior does not establish that administering a preparation reverses osteoporosis symptoms or prevents fractures.
This is because local signals from various cytokines and growth factors can regulate the bone tissue repair cascade by inducing osteoprogenitor cell migration, cell differentiation, proliferation, revascularization, and extracellular spaces. MSC-derived exosomes are discussed as a possible research approach in the cited 2018 review. [2] Research on osteogenesis, osteoclastogenesis and angiogenesis concerns different biological processes. The linked 2003 osteoclast-mechanism review is not a clinical trial demonstrating that MSC exosomes halt bone loss in osteoporosis patients.
Mesenchymal Stem Cells in Osteoporosis Research
Studies examine age-related changes in MSC function and osteogenic differentiation. Umbilical-cord stromal cells, blood-forming cells and bone-marrow-derived MSCs are different populations; their properties should not be combined into one list of clinical advantages. No cell-source label establishes absence of malignant-transformation risk. Reference [5] reports an in vitro proteomic study under high-glucose conditions. It does not demonstrate improved clinical treatment efficacy, and it should not be attributed to this center without evidence of that relationship. [5]
Paracrine Effects on Bone Regeneration
Paracrine research studies how released factors affect other cells. Growth-factor secretion is a mechanism to investigate, rather than proof of superior bone repair. When reading stem-cell research, distinguish the experimental model, actual preparation and measured outcome from a claim about patient benefit.
The Regeneration Center Osteoporosis Protocol
Clinical assessment before any intervention: Ask which cell preparation is proposed, the intended outcome, dose and administration route, supporting evidence, alternatives and procedure-specific risks. A proposed route of administration should be assessed on its own evidence and risks, rather than inferred from a general cell-therapy discussion.
Rehabilitation Post-Treatment: Physical Rehabilitation in Bangkok is optional but strongly recommended. Complete physical rehab services post-therapy can be provided upon request for 2-3 hours per day and up to 5 days per week.
Treatment and travel scheduling should be agreed only after the individual assessment. Medical and travel visas for extended accommodations at a hotel or apartment for the patient and family can also be provided upon request.
Bone and bone marrow
A cutaway of the upper femur showing compact bone, trabecular bone and marrow.
Osteoporosis Treatment Guidelines & Requirements in 2026
The number of treatment and follow-up days depends on the individual clinical plan. Due to the varying degrees of severity, our medical team will need to evaluate potential patients to establish an appropriate protocol. Upon completion of the therapy evaluation, a detailed treatment plan will be provided that includes the exact number of required days and the total medical costs.
An individual assessment does not guarantee benefit from a cell-based intervention. Ask how fracture events, function and adverse effects would be measured and compared with current osteoporosis care. To learn more about MSC+ Stem Cell treatment for Osteoporosis and whether it may be suitable for you, please contact us today.
Published Clinical Citations
[1] ^ Hu L, Yin C, Zhao F, Ali A, Ma J, Qian A. Mesenchymal Stem Cells: Cell Fate Decision to Osteoblast or Adipocyte and Application in Osteoporosis Treatment. Int J Mol Sci. 2018 Jan 25;19(2):360. doi: 10.3390/ijms19020360. PMID: 29370110; PMCID: PMC5855582.
[2] ^ Li Y, Jin D, Xie W, Wen L, Chen W, Xu J, Ding J, Ren D, Xiao Z. Mesenchymal Stem Cells-Derived Exosomes: A Possible Therapeutic Strategy for Osteoporosis. Curr Stem Cell Res Ther. 2018;13(5):362-368. doi: 10.2174/1574888X13666180403163456. PMID: 29623851.
[3] ^ Aghebati-Maleki L, Dolati S, Zandi R, Fotouhi A, Ahmadi M, Aghebati A, Nouri M, Kazem Shakouri S, Yousefi M. Prospect of mesenchymal stem cells in therapy of Osteoporosis: A review. J Cell Physiol. 2019 Jun;234(6):8570-8578. doi: 10.1002/jcp.27833. Epub 2018 Nov 29. PMID: 30488448.
[4] ^ Rudiansyah M, El-Sehrawy AA, Ahmad I, Terefe EM, Abdelbasset WK, Bokov DO, Salazar A, Rizaev JA, Muthanna FMS, Shalaby MN. Osteoporosis treatment by mesenchymal stromal/stem cells and their exosomes: Emphasis on signaling pathways and mechanisms. Life Sci. 2022 Oct 1;306:120717. doi: 10.1016/j.lfs.2022.120717. Epub 2022 Jul 2. PMID: 35792178.
[5] ^ Aswamenakul K, Klabklai P, Pannengpetch S, Tawonsawatruk T, Isarankura-Na-Ayudhya C, Roytrakul S, Nantasenamat C, Supokawej A. Proteomic study of in vitro osteogenic differentiation of mesenchymal stem cells in high glucose condition in Thailand. Mol Biol Rep. 2020 Oct;47(10):7505-7516. doi: 10.1007/s11033-020-05811-x. Epub 2020 Sep 11. PMID: 32918125.